Analyzing Cumberland Pharmaceuticals (NASDAQ:CPIX) and Nanobiotix (NASDAQ:NBTX)

Cumberland Pharmaceuticals (NASDAQ:CPIX) and Nanobiotix (NASDAQ:NBTX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, valuation, institutional ownership, dividends, earnings and risk.

Insider and Institutional Ownership

15.5% of Cumberland Pharmaceuticals shares are owned by institutional investors. Comparatively, 38.8% of Nanobiotix shares are owned by institutional investors. 44.9% of Cumberland Pharmaceuticals shares are owned by insiders. Comparatively, 3.5% of Nanobiotix shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current ratings and target prices for Cumberland Pharmaceuticals and Nanobiotix, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cumberland Pharmaceuticals	1	0	0	0	1.00
Nanobiotix	1	1	4	0	2.50

Nanobiotix has a consensus price target of $20.00, indicating a potential downside of 4.08%. Given Nanobiotix’s stronger consensus rating and higher possible upside, analysts clearly believe Nanobiotix is more favorable than Cumberland Pharmaceuticals.

Profitability

This table compares Cumberland Pharmaceuticals and Nanobiotix’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cumberland Pharmaceuticals	-8.06%	5.13%	1.92%
Nanobiotix	N/A	N/A	N/A

Earnings and Valuation

This table compares Cumberland Pharmaceuticals and Nanobiotix”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cumberland Pharmaceuticals	$37.87 million	1.54	-$6.48 million	($0.24)	-16.29
Nanobiotix	$39.18 million	25.76	-$73.73 million	N/A	N/A

Cumberland Pharmaceuticals has higher earnings, but lower revenue than Nanobiotix.

Risk and Volatility

Cumberland Pharmaceuticals has a beta of -0.52, suggesting that its share price is 152% less volatile than the S&P 500. Comparatively, Nanobiotix has a beta of 0.7, suggesting that its share price is 30% less volatile than the S&P 500.

Summary

Nanobiotix beats Cumberland Pharmaceuticals on 8 of the 12 factors compared between the two stocks.

About Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Further, it develops a clinical program for the use of ifetroban to treat progressive fibrosing interstitial lung diseases. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.

About Nanobiotix

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.